- Home
- DT vs BAX Comparison
DT vs BAX Comparison
Compare DT & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | BAX |
|---|---|---|
| Founded | 2005 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.2B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | DT | BAX |
|---|---|---|
| Price | $35.58 | $18.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 24 | 9 |
| Target Price | ★ $52.63 | $21.00 |
| AVG Volume (30 Days) | 5.6M | ★ 7.0M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.22% |
| EPS Growth | ★ 205.77 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | $1,698,683,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $21.74 | $1.92 |
| Revenue Next Year | $14.85 | $2.29 |
| P/E Ratio | $74.14 | ★ N/A |
| Revenue Growth | ★ 18.75 | 5.72 |
| 52 Week Low | $31.64 | $15.73 |
| 52 Week High | $57.55 | $32.68 |
Technical Indicators
Market Signals| Indicator | DT | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 62.03 |
| Support Level | $35.21 | $17.69 |
| Resistance Level | $38.84 | $18.89 |
| Average True Range (ATR) | 1.46 | 0.60 |
| MACD | -0.08 | 0.31 |
| Stochastic Oscillator | 62.13 | 86.13 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.